After kidney ischemia/reperfusion (I/R) injury, monocytes home to the kidney and differentiate into activated macrophages. Whereas proinflammatory macrophages contribute to the initial kidney damage, an alternatively activated phenotype can promote normal renal repair. The microenvironment of the kidney during the repair phase mediates the transition of macrophage activation from a proinflammatory to a reparative phenotype. In this study, we show that macrophages isolated from murine kidneys during the tubular repair phase after I/R exhibit an alternative activation gene profile that differs from the canonical alternative activation induced by IL-4-stimulated STAT6 signaling. This unique activation profile can be reproduced in vitro by stimulation of bone marrow-derived macrophages with conditioned media from serum-starved mouse proximal tubule cells. Secreted tubular factors were found to activate macrophage STAT3 and STAT5 but not STAT6, leading to induction of the unique alternative activation pattern. Using STAT3-deficient bone marrow-derived macrophages and pharmacologic inhibition of STAT5, we found that tubular cell-mediated macrophage alternative activation is regulated by STAT5 activation. Both in vitro and after renal I/R, tubular cells expressed GM-CSF, a known STAT5 activator, and this pathway was required for in vitro alternative activation of macrophages by tubular cells. Furthermore, administration of a neutralizing antibody against GM-CSF after renal I/R attenuated kidney macrophage alternative activation and suppressed tubular proliferation. Taken together, these data show that tubular cells can instruct macrophage activation by secreting GM-CSF, leading to a unique macrophage reparative phenotype that supports tubular proliferation after sterile ischemic injury.
Macrophages are key participants in regulating the inflammatory response to infections and sterile injuries. Macrophages are activated in response to pathogens and endogenous injury stimuli. The inflammation that ensues acts to eliminate pathogens/toxins, restore tissue homeostasis, and promote tissue repair. Broadly defined, macrophage activation has been divided into two major subtypes: classically activated proinflammatory M1 macrophages and alternatively activated anti-inflammatory M2 macrophages. Classically activated M1 macrophages are induced by IFN-g and activation of Toll-like receptors and promote antimicrobial responses downstream of STAT1 and NF-kB signaling, respectively. Alternatively activated macrophages were first defined as IL-4/IL-13-induced macrophages seen in parasitic infections but have subsequently been detected in multiple types of infectious and sterile tissue injuries. M2 macrophages have been typically subcategorized into M2a woundhealing macrophages induced by IL-4/IL-13 activation of the IL-4Ra-STAT6 signaling pathway and regulatory M2b/c macrophages, which are activated by immune complexes and IL-10 or TGF-b, respectively. 1 These categories have largely been defined in vitro with individual stimuli. In vivo, macrophage differentiation and activation of effector functions during the inflammatory response are dictated by a dynamic and complex microenvironment. Investigation of in vivo macrophages in a wide variety of disease models associated with inflammation, both infectious and sterile, has shown a diverse spectrum of macrophage phenotypes that are temporally and functionally dynamic. 2 Identification of the in vivo signaling pathways that govern macrophage activation and regulate macrophage effector functions may, therefore, provide therapeutic targets to promote inflammation resolution and tissue repair.
In sterile ischemic kidney injury models, macrophages seem to play roles in all phases of the injury process, including the initial injury, subsequent repair, and late fibrosis. 3, 4 Within 24 hours after ischemia/reperfusion (I/R) injury, monocytes are recruited to the kidney, where they differentiate into macrophages. Proinflammatory macrophages predominate during the early injury phase, during which tubular apoptosis is prominent. During the tubular repair phase, when tubular cells are proliferating and repopulating the denuded basement membrane, kidney macrophages begin to express markers of alternative activation. Macrophage depletion studies suggest that the functional phenotypes of the macrophages correlate with each phase. [5] [6] [7] [8] [9] [10] [11] Our previous in vivo studies using fluorescently tagged ex vivo IFN-g-primed macrophages suggested that signals within the injured kidney were sufficient to induce this proinflammatory to anti-inflammatory phenotypic switch in infiltrating macrophages. 10 Both in vivo studies using IL-4Ra null mice and in vitro coculture studies suggest that the primary signal for alternative macrophage activation in the injured kidney uses an IL-4Ra-independent pathway. 10 In this study, we show that the pattern of in vivo alternative macrophage activation after I/R injury is distinct from that seen after in vitro IL-4 stimulation but consistent with the pattern of activation seen after macrophage exposure to tubular cell conditioned media (CM). To determine the mechanism by which tubular cells can promote macrophage alternative activation, we defined the signaling pathways activated in macrophages by secreted tubular factors. In vitro studies with primary bone marrow-derived macrophages (BMMs) and CM from serum-starved mouse proximal tubule (MPT) cells showed that tubular cell-secreted factors activate JAK-STAT (STAT3 and STAT5) pathways in macrophages. Using BMMs from LysM-Cre;Stat3 fl/fl mice as well as pharmacologic inhibition of STAT5, we found that tubule cell-mediated macrophage alternative activation is regulated by STAT5 activation. GM-CSF, a well known STAT5 activator, is upregulated in renal proximal tubule cells after I/R injury. We found that GM-CSF is secreted by MPT cells and required to induce alternative activation in BMMs. Functional blockade of GM-CSF with a neutralizing antibody both in vitro and in vivo attenuates tubular-mediated macrophage alternative activation, resulting in decreased tubular cell proliferation during the repair phase after kidney injury.
RESULTS

Tubular-Mediated Alternative Activation Is IL-4-STAT6 Independent
We have found that proinflammatory macrophages cocultured with MPT cells or primary tubular epithelial cells show increased expression of the classic alternative activation genes arginase-1 (Arg1) and Cd206 (mannose receptor), which is independent of IL-4Ra-STAT6 signaling 10 (Supplemental Figure 1) . To determine if tubular cell-induced alternative activation is distinct from IL-4-induced alternative activation, naïve BMMs were stimulated with IL-4 or CM from serum-starved MPT cells. The gene expression profiles of IL-4-compared with MPT CM-treated macrophages show both overlapping (Arg1 and Cd206) ( Figure 1A ) and divergent gene expression. Msr1 is induced by MPT CM but not IL-4 ( Figure 1B ), whereas Dectin-1, Fizz1, Ym1, and Igf-1 are specific to IL-4-induced macrophage alternative activation ( Figure 1C ). To determine the relevance of these distinct alternative activation profiles for in vivo macrophage activation, macrophages were flow-sorted from control kidneys and ischemically injured kidneys on day 5 after reperfusion (the time at which we detected increased Arg1 and Cd206 expression 10 ) and analyzed for alternative activation gene expression. Consistent with the tubular cell activation profile, Msr1 expression is upregulated in macrophages at day 5 after I/R injury compared with macrophages from uninjured kidneys, whereas the expression of downstream IL-4 gene targets (Dectin-1, Fizz1, and Ym1 12 ) is not induced ( Figure 1D ). Of note, Igf-1 expression is upregulated on day 5 after I/R, suggesting that either there is selective IL-4 signaling to induce Igf-1 but not other IL-4 targets or a third pathway (nontubular and non-IL-4) may be responsible for Igf-1 expression.
Tubular Factors That Induce Macrophage Alternative Activation Are Basolaterally Secreted Proximal tubular cells are polarized epithelia, with the apical surface facing the tubule lumen exposed to the glomerular filtrate and the basolateral surface attached to the basement membrane facing the interstitium. After I/R injury, macrophages traffic to the interstitium of the kidney and line areas of tubular damage adjacent to the tubular basement membrane. 10 To model in vivo polarity and determine whether the polarity of secreted tubular factors would be physiologically relevant in activating macrophages in the interstitium, MPT cells were grown to confluency on 0.4-mm Transwell inserts, and CM were collected from either the apical-or basolateral-facing chambers (Figure 2A ). The basolateral MPT CM induced significantly higher expression of Arg1 and Cd206 than the apical CM ( Figure 2 , B and C), consistent with the model that tubular cell-secreted factors can signal to macrophages in vivo.
Tubular-Secreted Factors Activate JAK-STAT Signaling Pathways
The JAK-STAT pathway is a major signaling pathway that regulates macrophage activation. [13] [14] [15] To determine whether a JAK-STAT signaling pathway other than IL-4Ra-STAT6 is involved in tubular cell-mediated macrophage activation, STATsignaling pathways were analyzed in naïve BMMs at various time points after exposure to MPT CM. Macrophage STAT3 and STAT5 were phosphorylated early (within 5 [STAT3] to 30 [STAT5] minutes after treatment with tubular CM) ( Figure 3A) , whereas STAT6 was not activated by CM. Compared with IFN-g-induced macrophages, STAT1 was not significantly activated. mRNA expression of the macrophage alternative activation markers Arg1, Cd206, and Msr1 was induced at 6-12 hours after treatment with tubular CM, whereas the expression of Igf-1 was not induced ( Figure 3B) .
A pan-JAK inhibitor, JAK inhibitor I, was used to determine whether JAK-STAT signaling is required for the induction of tubular cell-mediated macrophage alternative activation. JAK inhibitor I efficiently inhibited MPT CM-induced STAT3 and STAT5 activation in BMMs ( Figure 4, A and B) . This JAK-STAT inhibition led to almost complete inhibition of ARG1 protein expression (Figure 4, A and B) and Arg1, Cd206, and Msr1 mRNA expression ( Figure 4C ).
Tubule Cell-Mediated Macrophage Activation Requires STAT5 but Not STAT3 Activation STAT3-dependent induction of alternative activation has been described through IL-10- 16 and more recently, MyD88-dependent autocrine production of IL-6, IL-10, and CSF-3 in mycobacteria-infected macrophages. 17 To determine whether STAT3 is required for tubular-mediated alternative activation in macrophages, a transgenic mouse model with myeloid-specific knockout of STAT3 was generated. LysM-Cre transgenic mice 18 with myeloid-specific expression of Cre recombinase were mated with Stat3 fl/fl mice. 19 Macrophage Stat3 deletion was efficient in BMMs from LysM-Cre;Stat3 fl/fl mice, and there was no detectable phosphorylation of STAT3 in LysM-Cre;Stat3 fl/fl BMMs treated with MPT CM ( Figure 5, A and B) . However, elimination of STAT3 activation did not affect CM-stimulated STAT5 activation or induction of ARG1 protein expression ( Figure 5, A and B) or Arg1, Cd206, and Msr1 mRNA expression ( Figure 5C ).
To determine whether STAT5 is required for tubular cellmediated macrophage activation, N9-((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide, a nonpeptidic small molecule ) over a 4-day period. The cells were washed, and media were changed to serum-free media with equal volumes (2 ml) within the insert (apical) and below within the cell culture well (basolateral) as shown. CM were collected 48 hours later. Naïve BMMs were then treated with vehicle media, apical CM, or basolateral CM. Cell lysates were collected at (B) 12 hours for mRNA expression (shown relative to Hprt) and (C) 24 hours for protein analysis (densitometry shown normalized to b-actin; n=3). Data are shown as means6SEMs. ACTB, b-actin; Basolat, basolateral; Exp, expression; veh, vehicle. *P,0.05; **P,0.01 (vehicle, apical, and basolateral).
STAT5 inhibitor that targets the SH2 domain of STAT5, 20 was used. The STAT5 inhibitor reduced MPT CM-induced STAT5 activation by approximately 70% (P=0.02) and significantly decreased Cd206, with a concomitant reduction in ARG1 protein and Arg1 and Msr1 mRNA expression that did not reach statistical significance ( Figure 6 ). These data suggest that STAT5 signaling rather than STAT3 is required for tubular cell-mediated macrophage alternative activation.
GM-CSF Expression Is Upregulated in the Kidney after I/R Injury and Precedes STAT5 Activation GM-CSF (or CSF2) is known to be a regulator of monocyte/ macrophage differentiation and mediates its actions through the activation of JAK2 and STAT5. 21, 22 We found that GM-CSF expression in the whole kidney is increased within 24 hours after ischemic injury and peaks on day 3, preceding detectable STAT5 activation and protein expression of the alternative activation markers ARG1 and CD206 seen on days 3-5 after I/R injury ( 
GM-CSF Secreted by Renal Tubular Cells is Required to Induce Alternative Activation in Macrophages
The observation that GM-CSF expression and macrophage alternative activation are sequential in vivo led us to hypothesize that GM-CSF secreted by tubular cells mediates STAT5-dependent macrophage alternative activation. Assessment of naïve macrophage activation in response to recombinant GM-CSF revealed that expression of Arg1, Cd206, and Msr1 was detectably induced at concentrations between 300 and 500 pg/ml, whereas maximal activation of Arg1 and Msr1 required much higher concentrations ( Figure 8A ). Interestingly, the concentration of GM-CSF in basolateral MPT CM was 374654.6 pg/ml, whereas GM-CSF levels in the apical MPT CM, which failed to induce alternative activation, were below the induction threshold (185.4625.4 pg/ml). To determine if tubular cell-secreted GM-CSF is required for in vitro macrophage alternative activation, naïve BMMs were treated with MPT CM with or without the addition of a GM-CSFneutralizing antibody. These experiments revealed that the neutralizing antibody to GM-CSF prevented STAT5 activation after either GM-CSF or MPT CM stimulation ( Figure 8 , B and C, quantified in Figure 8D ). Furthermore, the neutralizing antibody effectively inhibited Arg1, Cd206, and Msr1 expression in response to MPT CM, showing that GM-CSF is the tubule-derived signal for STAT5 activation and required for tubule cell-induced alternative activation ( Figure 8E) .
Comparison of Arg1, Cd206, and Msr1 expression in response to macrophage stimulation with either MPT CM or GM-CSF revealed that Arg1 and Msr1 were induced to a greater degree by MPT CM than GM-CSF at concentrations comparable with those in MPT CM (compare the columns for 300 and 500 pg/ml in Figure 8A with MPT CM in Figure 8E ). In contrast, Cd206 expression seems to be maximally stimulated by GM-CSF in this dose range. These findings suggest that MPT CM contains factors in addition to GM-CSF that can induce Arg1 and Msr1 expression. Macrophage colonystimulating factor (M-CSF) is known to promote M2 macrophage activation, expressed in proximal tubular cells after tubular injury, and expressed by MPT cells at mRNA levels 80-fold higher than Csf2 23-26 (Supplemental Figure 3, A and B) . To determine if M-CSF and GM-CSF act in concert to promote tubule-induced alternative activation, BMMs were treated with GM-CSF with or without M-CSF. These experiments revealed that M-CSF alone did not activate STAT5 and was insufficient to induce Arg1, Cd206, and Msr1 expression, whereas the combination of GM-CSF and M-CSF induced both Arg1 and Msr1 to a greater degree than GM-CSF did alone (Supplemental Figure 3, C and D) . In contrast, M-CSF did not accentuate GM-CSF-stimulated expression of Cd206. These data show that GM-CSF is both necessary and sufficient for tubule cellmediated STAT5 phosphorylation and Cd206 expression, whereas maximal expression of other markers of alternative macrophage activation requires GM-CSF plus additional factors, such as M-CSF.
Blockade of GM-CSF after Renal I/R Injury Attenuates Kidney Macrophage Alternative Activation and Slows Reparative Tubule Proliferation
To define the relevance of GM-CSF-induced signaling for macrophage activation in vivo, mice were subjected to bilateral renal I/R injury followed by administration of the GM-CSF-neutralizing antibody starting at 36 hours after I/R injury, with kidneys harvested for macrophage expression profiling on day 5 after reperfusion ( Figure 9A ). The timing of the initiation of GM-CSF-neutralizing antibody was chosen such that the initial proinflammatory macrophage influx and tubule injury, both of which peak at 24 hours, 10 were unaltered. As expected, the initial tubular injury at 24 hours after reperfusion is identical in the two groups, which is reflected by the creatinine increase to 0.3 on day 1 ( Figure 9B ). This protocol of one time daily GM-CSF blockade led to a modest decrease in whole-kidney STAT5 activation on day 5 after I/R injury ( Figure 9 , C and D) but did achieve a significant decrease in the mRNA expression of Cis, a well known GM-CSF-STAT5 downstream gene target, 27 by isolated kidney macrophages ( Figure 9E ). Although the total number of CD45 + F4/80 + CD11c 2 macrophages recruited to the kidney and the number of CD45 + F4/80 + CD11c + cells was not significantly changed by GM-CSF blockade ( Figure  9F ) (data not shown), the expression of the alternative activation markers Arg1, Cd206, and Msr1 were significantly reduced in F4/80 + CD11c 2 macrophages, whereas Igf-1 expression was unchanged ( Figure 9G ). This partial inhibition of STAT5 activation and macrophage alternative activation significantly reduced tubular cell proliferation on day 5 ( Figure 9 , H-J) but did not affect GFR as estimated by serum creatinine ( Figure 9B ).
DISCUSSION
The signals that instruct macrophages to alter their gene expression profile and their functional repertoire to promote tubular repair after renal I/R injury are unknown. Our previous studies showed that macrophages transition from a proinflammatory state during the tubular apoptotic injury phase to a reparative state during the tubular proliferative phase. We found that tubular cells induce macrophage alternative activation in vitro through an IL-4Ra-independent pathway. Here, we sought to investigate the mechanism by which tubular cells can promote macrophage alternative activation.
Because JAK-STAT pathways are critical in regulating macrophage activation, we first determined whether a JAK-STAT pathway other than IL-4Ra-STAT6 was involved in tubular cell-mediated macrophage alternative activation. Using mRNA expression profiling of macrophages isolated from injured kidneys, comparisons of IL-4-and tubular CM-induced macrophages, STAT3-deficient BMMs, and STAT5 inhibition, we identified GM-CSF as a tubule-derived STAT5 activator mediating a unique macrophage alternative activation phenotype that differs from the canonical Th2 IL-4-induced alternative activation state. GM-CSF was first described for its ability to generate granulocyte and macrophage populations from bone marrow precursor cells. 28 It has become evident that GM-CSF also plays important roles in the activation and function of more mature myeloid cells in the setting of infection and inflammation. 29 Macrophages differentiated in vitro in the presence of GM-CSF or M-CSF have basal cytokine expression profiles and responsiveness to LPS similar to M1 and M2 macrophages, respectively. 30, 31 However, recent characterization of global gene expression profiles of GM-CSF-and M-CSF-derived macrophages suggests that the M1 and M2 categorizations of these cells may be limited, especially when comparing murine and human macrophage gene expression. 32 Furthermore, because the M1/M2 designation of GM-CSF-and M-CSF-differentiated BMMs is primarily on the basis of in vitro macrophages stimulated with LPS, it is unclear whether this designation holds true in the setting of sterile inflammation and in vivo in the presence of additional stimuli. The complexity of GM-CSF biology is evident, because it is implicated in inflammatory conditions, such as rheumatoid arthritis and crescentic GN, 33 but also, as an inducer of M2 markers in microglia/macrophages surrounding glioblastoma tumor cells. 34 Nonhematopoietic cells, such as vascular smooth muscle cells and colon epithelial cells, have been reported to be important sources of GM-CSF, mediating atherogenic monocyte activation 35 and promoting colonic epithelial cell proliferation in colitis, 36 respectively. In addition, GM-CSF has been associated to Th2 immune responses in allergic lung inflammation. 37, 38 Thus, macrophage activation by GM-CSF and M-CSF treatment seems to be highly context dependent. 39 In our model of mouse renal I/R injury, an increase in GM-CSF expression within the kidney was detectable within 24 hours after I/R and peaked on day 3, at which time proximal tubule cell expression of GM-CSF significantly increased. STAT5 activation and expression of alternative activation markers in macrophages follow during the tubular repair phase (3-5 days after I/R). General depletion of macrophages during this tubular repair phase results in decreased reparative tubular proliferation, suggesting that the induction of alternative activation genes in macrophages during this time is critical for macrophage-mediated tubular repair. 9, 10 These studies used in vivo GM-CSF blockade after renal I/R to assess the importance of this pathway in macrophage activation and tubule repair. One time daily injection of the GM-CSF-neutralizing antibody achieved only a partial reduction in STAT5 activation in the injured kidney at the one time point assessed (day 5), but the expression of all three alternative activation markers shown to require GM-CSF-STAT5 signaling in vitro were significantly reduced in macrophages isolated from these kidneys. Furthermore, the proliferation of tubular cells that is known to underlie effective kidney repair was significantly reduced after GM-CSF blockade. Although the above observations provide strong support for the importance of tubule cell-secreted GM-CSF in promoting alternative macrophage activation after kidney injury, it is interesting to note that GFR, as estimated by serum creatinine, was not reduced in the mice exposed to the GM-CSF-neutralizing antibody. It remains to be determined whether this is because we achieved only a partial blockade of GM-CSF signaling with the once a day injection of the neutralizing antibody (compare the modest decrease in STAT5 phosphorylation and Cd206 and Msr1 expression achieved with the neutralizing antibody in vivo with the more robust effect in vitro) or because GM-CSF-STAT5-independent factors, such as tubule-secreted M-CSF [24] [25] [26] and/or macrophage-secreted IGF-1, can provide sufficient reparative signals to partially compensate for the loss of GM-CSF signaling. Although there was no difference in serum creatinine, decreased tubular proliferation during the repair phase can have long-term consequences, such as fibrosis. Serum creatinine can return to baseline levels, even when there is significant induction of late tubular fibrosis, 40 suggesting that hyperfiltration can underlie normalization of creatinine and mask failure of normal repair. Although this study has identified an important pathway mediating the alternative activation kidney macrophages after I/R injury, the modest ability of the GM-CSF-neutralizing antibody to prevent STAT5 activation in vivo will likely limit its use for studying these late outcomes.
Our data show that the full expression of alternative activation after tubule injury requires factors other than GM-CSF and are consistent with previous reports of M-CSF as an activator of the reparative macrophage phenotype. [24] [25] [26] GM-CSF and M-CSF are both secreted by tubular cells and seem to serve as coinducers for maximizing macrophage expression of protective factors, such as arginase-1. In contrast, secreted tubular factors do not induce macrophage Igf-1 expression, although Igf-1 expression is upregulated in kidney macrophages at day 5 after I/R ( Figure  1D ). IGF-1 is a well known inducer of tubule cell proliferation, 41 and the mechanism behind its macrophage expression after kidney injury clearly deserves additional study. Identification of these signals within the microenvironment of the postischemic kidney will further enhance our understanding of how reparative macrophages are activated.
Taken together, our data show that GM-CSF secreted by tubular epithelial cells after I/R injury mediates a novel STAT5-dependent macrophage activation profile that promotes tubular proliferation during kidney repair. Future studies using conditional knockout of the GM-CSF-STAT5 pathway will be needed to fully address the functional significance of this unique mode of alternative macrophage activation in the process of normal tubule repair as well as maladaptive fibrosis after kidney injury. 
CONCISE METHODS
Animals
In Vitro Cell Culture and CM Protocol
BMMs were isolated and cultured in the presence of L929 supernatant as per the protocol of Cui et al. 43 and as previously described. 10 In all in vitro BMM experiments, after 7 days of differentiation in the presence of L929 supernatant, macrophages were passaged and plated in MEM-a media containing 10% FBS without additional growth factors (i.e., no L929, M-CSF, or GM-CSF) for 24 hours before initiation of experimental conditions. For in vitro polarization, BMMs were stimulated with either 100 units/ml murine recombinant IFN-g (11276905001; Roche) or 20 ng/ml murine recombinant IL-4 (I1020; Sigma-Aldrich). BMMs were treated with recombinant mouse GM-CSF and M-CSF at specified concentrations. BMMs were stimulated with MPT CM (described below) for various time points. For MPT CM, pathogen-free MPT cells (BU-MPT immortalized cells 44 ) were grown to confluence, washed with PBS three times, and cultured in serum-free DMEM:F12 media (Gibco). Media supernatant was Figure 8 . GM-CSF secreted by tubular cells promotes alternative activation of macrophages. (A) BMMs were treated with recombinant mouse GM-CSF at the indicated concentrations for 12 hours. Cell lysates harvested for RNA isolation and mRNA expression are shown relative to Hprt. **P,0.01; ***P,0.001 versus 0 pg/ml. (B) Five micrograms per milliliter neutralizing (Neut) GM-CSF antibody or isotype (Iso) antibody was added to culture media containing 300 pg/ml GM-CSF (GM) and incubated for 3 hours at 37°C before treating naïve BMMs. Cell lysates of treated BMMs were harvested at 30 minutes for Western blot analysis of pSTAT5. (C-E) Five micrograms per milliliter Neut GM-CSF antibody or Iso antibody was added to MPT CM and incubated for 3 hours at 37°C before treating naïve BMMs. Cell lysates of BMMs harvested at (C) 30 minutes for Western blot analysis of pSTAT5 (densitometry in D normalized to loading control b-actin is shown relative to vehicle-treated controls) and (E) 12 hours for RNA. mRNA expression is shown relative to Hprt (n=3 for all experiments). Data are shown as means6SEMs. ACTB, b-actin; Exp, expression; Veh, vehicle. *P,0.05; **P,0.01; ***P,0.001; ****P,0.0001. collected after 48 hours, centrifuged to remove debris, and filtered with a 0.2-mm filter. All BMM and MPT CM experiments were performed with 10% FBS containing MEM-a media and either serum-free DMEM:F12 media or serum-free MPT CM at a 1:1 ratio.
Collection of apical and basolateral CM was performed by plating 0. MPT cells deemed to be free of mycoplasma contamination were used to collect CM. Mycoplasma testing was performed with the LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich). MPT CM were also tested for endotoxin using the ToxinSensor Gel Clot Endotoxin Assay Kit (L00351; Genscript). MPT CM endotoxin level was tested to be ,0.25 endotoxin units (EU) /ml (1 EU/ml is approximately 0.1 ng/ml). Of note, MEM-a media containing 10% FBS used as the vehicle control media tested positive for endotoxin levels.0.25 EU/ml (industry standard for FBS is ,10 EU/ml).
Renal I/R Model
Male 8-to 10-week-old C57BL/6 mice (National Institutes of Health/ National Cancer Institute) were anesthetized with intraperitoneal ketamine (100 mg/kg) and xylazine (10 mg/kg) and then subjected to renal I/R using a modified approach to that previously described. 10 Briefly, both the right and left renal pedicles were isolated through a midline abdominal incision and clamped for 24 minutes using a nontraumatic microaneurysm clip (Fine Science Tools). Mice were kept at 37°C using a warming pad, and reperfusion of both kidneys was confirmed after clamp release. Mice were given 1 ml normal saline intraperitoneally to prevent dehydration. Mice were euthanized on days 0, 1, 3, and 5 after reperfusion. Kidney tissue was harvested for histology, immunohistochemistry, and FACS sorting for RNA isolation. For in vivo GM-CSF neutralization experiments, five doses of 300 mg anti-mouse GM-CSFneutralizing antibody or rat IgG isotype control were injected intraperitoneally daily starting 36 hours after I/R injury. Mice were euthanized on day 5; tissue and blood were collected for analysis. Serum creatinine was measured by HPLC (Yale Mouse Metabolic Phenotyping Center).
Isolation of Kidney Proximal Tubule Cells and Macrophages.
Kidney macrophage isolation at day 5 of I/R injury was performed with kidney digestion as previously described. 10 
Immunostaining
Kidneys were perfused with PBS, fixed with 10% neutral buffered formalin, and processed for histology (hematoxylin and eosin; paraffin blocks) or immunostaining (5-mm cryostat sections). After antigen retrieval with BD Retrievagen A, sections were permeabilized in methanol for 10 minutes at 220°C. The sections were then blocked at room temperature using PBS containing 0.1% BSA and 10% donkey serum. The following primary antibodies were used: anti-F4/80 (clone BM8; eBioscience and anti-pSTAT5 (9359; Cell Signaling Technology). Ki67 immunohistochemistry staining was performed by Yale Research histology. Quantification of cells expressing the specified marker was performed in a blinded fashion by counting positive cells per total cells (identified as 49,6-diamidino-2-phenylindole+nuclei for immunofluorescence staining) in 10 randomly chosen 3400 fields from the outer medulla. Images were taken at 3400 using a Nikon microscopy system.
Western Blot
Lysates of mouse kidney were prepared by homogenization in 0.5 ml RIPA buffer containing SDS (Teknova) with Halt protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). Cultured cells were also lysed directly in RIPA buffer containing SDS, supplemented with a protease and phosphatase inhibitor cocktail. Equal amounts of protein were loaded, and electrophoresis was performed in 10% polyacrylamide separating gel/5% stacking gel or precast Mini-Protean TGX 4%-15% gradient gel (Bio-Rad). Proteins were transferred to PVDF membrane and blocked with 5% milk in Tris-buffered saline with Tween 20 for 1 hour. Membranes were incubated overnight at 4°C. Blots were then washed and incubated with secondary antibody for 1 hour at room temperature. After washing, the second antibody was visualized by chemiluminescence reagents (PerkinElmer).
ELISA GM-CSF in MPT CM was measured by sandwich ELISA using antimouse GM-CSF antibody (554404; BD Pharmigen) as a capture antibody and biotin anti-mouse GM-CSF antibody (554407; BD Pharmigen) as a detection antibody, with recombinant mouse GM-CSF (R&D) as the standard.
RNA Isolation, RT-PCR, and Quantitative Real-Time PCR
RNA was extracted with an RNeasy Mini Kit (Qiagen) and reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad). Gene expression analysis was determined by quantitative real-time PCR (iTaq Universal Sybr Green Supermix; Bio-Rad) using a CFX96 (Bio-Rad) and normalized to Hprt. Data are expressed using the comparative threshold cycle (dCt) method, and mRNA ratios are given by 2 2dCt or fold difference (ddCt) relative to a control. Primers used include previously published primers for Arg1, Cd206, Hprt, Igf-1, Msr1, Tgfb1, and Ym1 10,45 as well as Cis forward: TCGGGAATCTGGGTGGTACT, reverse: GGGTGCTGTCTCGAACTAGG; Csf1 forward: GCTGGATGAT-CCTGTTTGCT, reverse: GCTGGAGAGGAGTCTCATGG; Csf2 forward: TGGTCTACAGCCTCTCAGCA, reverse: CCGTAGACCCTGCTC-GAATA; Dectin1 forward: GGAATCCTGTGCTTTGTGGT, reverse: TAGTTTGGGATGCCTTGGAG; and Fizz1 forward: AGGAAC-TTCTTGCCAATCCA, reverse: CTGGGTTCTCCACCTCTTCA.
Statistical Analyses
All results are expressed as means6SEMs. Comparisons were tested with unpaired t tests and one-or two-way ANOVAs with post-test Bonferroni or Tukey multiple comparison analyses where appropriate using Prism 6.0 (GraphPad Software, Inc.). Data are presented as means6SEMs. P#0.05 was considered to be statistically significant.
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